The therapeutic potential of CFTR modulators for COPD and other airway diseases

Current Opinion in Pharmacology

Volumn 34, Issue , 2017, Pages 132-139

  Solomon, George M ^a,d   Fu, Lianwu ^c,d   Rowe, Steven M ^a,b,c,d   Collawn, James F ^c,d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; STEROID;

ASTHMA; BRONCHIECTASIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DRUG INDICATION; GENE EXPRESSION; HUMAN; MUCOLYSIS; NON CYSTIC FIBROSIS BRONCHIECTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; RESPIRATORY TRACT DISEASE; REVIEW; SMOKING; ANIMAL; LUNG DISEASE; METABOLISM;

ANIMALS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; LUNG DISEASES; PHOSPHODIESTERASE 4 INHIBITORS; SMOKING;

EID: 85033367251     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2017.09.013     Document Type: Review

References (73)

1. Kim, V., Han, M.K., Vance, G.B., Make, B.J., Newell, J.D., Hokanson, J.E., Hersh, C.P., Stinson, D., Silverman, E.K., Criner, G.J., Investigators, C.O., The chronic bronchitic phenotype of copd: an analysis of the copdgene study. Chest 140 (2011), 626–633.
2. Kim, V., Criner, G.J., Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187 (2013), 228–237.
3. Kim, V., Sternberg, A.L., Washko, G., Make, B.J., Han, M.K., Martinez, F., Criner, G.J., National Emphysema Treatment Trial Research G. Severe chronic bronchitis in advanced emphysema increases mortality and hospitalizations. COPD 10 (2013), 667–678.
4. Raju, S.V., Solomon, G.M., Dransfield, M.T., Rowe, S.M., Acquired cystic fibrosis transmembrane conductance regulator dysfunction in chronic bronchitis and other diseases of mucus clearance. Clin Chest Med 37 (2016), 147–158 Review that describes the mechanistic basis for acquired CFTR dysfunction in chronic bronchitis.
5. Sloane, P.A., Shastry, S., Wilhelm, A., Courville, C., Tang, L.P., Backer, K., Levin, E., Raju, S.V., Li, Y., Mazur, M., Byan-Parker, S., et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS ONE, 7, 2012, e39809.
6. Cantin, A.M., Hanrahan, J.W., Bilodeau, G., Ellis, L., Dupuis, A., Liao, J., Zielenski, J., Durie, P., Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 173 (2006), 1139–1144 First evidence that CFTR expression was decreased by exposure to cigarette smoke in vitro and in vivo. They showed that acquired CFTR deficiency occurs in the nasal respiratory epithelium of cigarette smokers and suggested that CFTR deficiency contributed to cigarette-induced diseases such as chronic bronchitis.
7. Dransfield, M.T., Wilhelm, A.M., Flanagan, B., Courville, C., Tidwell, S.L., Raju, S.V., Gaggar, A., Steele, C., Tang, L.P., Liu, B., Rowe, S.M., Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest 144 (2013), 498–506 This important study compared lower airway CFTR activity in current and former smokers with COPD, current smokers without COPD, and nonsmokers and found that smokers with and without COPD had reduced lower airway activity compared with nonsmokers and suggested that CFTR dysfunction contributed to COPD pathogenesis.
8. Zhao, R., Liang, X., Zhao, M., Liu, S.L., Huang, Y., Idell, S., Li, X., Ji, H.L., Correlation of apical fluid-regulating channel proteins with lung function in human copd lungs. PLOS ONE, 9, 2014, e109725.
9. Courville, C.A., Tidwell, S., Liu, B., Accurso, F.J., Dransfield, M.T., Rowe, S.M., Acquired defects in CFTR-dependent beta-adrenergic sweat secretion in chronic obstructive pulmonary disease. Respir Res, 15, 2014, 25.
10. Courville, C.A., Raju, S.V., Liu, B., Accurso, F.J., Dransfield, M.T., Rowe, S.M., Recovery of acquired cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction following smoking cessation. Am J Respir Crit Care Med 192:12 (2015), 1521–1524.
11. Rennolds, J., Butler, S., Maloney, K., Boyaka, P.N., Davis, I.C., Knoell, D.L., Parinandi, N.L., Cormet-Boyaka, E., Cadmium regulates the expression of the CFTR chloride channel in human airway epithelial cells. Toxicol Sci 116 (2010), 349–358.
12. Raju, S.V., Jackson, P.L., Courville, C.A., McNicholas, C.M., Sloane, P.A., Sabbatini, G., Tidwell, S., Tang, L.P., Liu, B., Fortenberry, J.A., Jones, C.W., et al. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med 188 (2013), 1321–1330 This significant paper illustrated that cigarette smoke affected other organ systems such as intestinal epithelium and showed that acrolein, a component of cigarette smoke, was higher in smokers and inhibited CFTR channel gating, and that a scavenger of acrolein, N-acetylcysteine, could reverse these effects.
13. Bodas, M., Van Westphal, C., Carpenter-Thompson, R., D, K.M., Vij, N., Nicotine exposure induces bronchial epithelial cell apoptosis and senescence via ros mediated autophagy-impairment. Free Radic Biol Med 97 (2016), 441–453.
14. Rasmussen, J.E., Sheridan, J.T., Polk, W., Davies, C.M., Tarran, R., Cigarette smoke-induced Ca2+ release leads to cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. J Biol Chem 289 (2014), 7671–7681.
15. Rowell, T.R., Tarran, R., Will chronic e-cigarette use cause lung disease?. Am J Physiol Lung Cell Mol Physiol 309 (2015), L1398–L1409.
16. Clunes, L.A., Davies, C.M., Coakley, R.D., Aleksandrov, A.A., Henderson, A.G., Zeman, K.L., Worthington, E.N., Gentzsch, M., Kreda, S.M., Cholon, D., Bennett, W.D., et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 26 (2012), 533–545 In this mechanistic study, the authors demonstrate that cigarette exposure directly leads to loss of CFTR from the cell surface and results in airway surface dehydration, leading to mucus stasis, and suggested that stategies for rehydrating the surface could provide a therapy for chronic bronchitis.
17. Leopold, P.L., O'Mahony, M.J., Lian, X.J., Tilley, A.E., Harvey, B.G., Crystal, R.G., Smoking is associated with shortened airway cilia. PLoS ONE, 4, 2009, e8157.
18. Le Gars, M., Descamps, D., Roussel, D., Saussereau, E., Guillot, L., Ruffin, M., Tabary, O., Hong, S.S., Boulanger, P., Paulais, M., Malleret, L., et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med 187 (2013), 170–179 This manuscipt provides a novel a link between neutrophil elastase-calpain activation and CFTR loss of function in bacterial lung infections relevant to CF. They demonstrate that neutrophil elastase degrades CFTR through activation of intracellular calpains.
19. Robinson, D.S., Hamid, Q., Ying, S., Tsicopoulos, A., Barkans, J., Bentley, A.M., Corrigan, C., Durham, S.R., Kay, A.B., Predominant th2-like bronchoalveolar t-lymphocyte population in atopic asthma. N Engl J Med 326 (1992), 298–304.
20. Sheehan, J.K., Richardson, P.S., Fung, D.C., Howard, M., Thornton, D.J., Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 13 (1995), 748–756.
21. Fahy, J.V., Dickey, B.F., Airway mucus function and dysfunction. N Engl J Med 363 (2010), 2233–2247.
22. Nakagome, K., Matsushita, S., Nagata, M., Neutrophilic inflammation in severe asthma. Int Arch Allergy Immunol 158:Suppl. 1 (2012), 96–102.
23. Evans, C.M., Kim, K., Tuvim, M.J., Dickey, B.F., Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med 15 (2009), 4–11.
24. Oguzulgen, I.K., Kervan, F., Ozis, T., Turktas, H., The impact of bronchiectasis in clinical presentation of asthma. South Med J 100 (2007), 468–471.
25. Sandford, A., The role of CFTR mutations in asthma. Can Respir J 19 (2012), 44–45.
26. Maurya, N., Awasthi, S., Dixit, P., Association of CFTR gene mutation with bronchial asthma. Indian J Med Res 135 (2012), 469–478.
27. Noone, P.G., Knowles, M.R., ‘CFTR-opathies’: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res 2 (2001), 328–332.
28. Goodwin, J., Spitale, N., Yaghi, A., Dolovich, M., Nair, P., Cystic fibrosis transmembrane conductance regulator gene abnormalities in patients with asthma and recurrent neutrophilic bronchitis. Can Respir J 19 (2012), 46–48.
29. Skowron-zwarg, M., Boland, S., Caruso, N., Coraux, C., Marano, F., Tournier, F., Interleukin-13 interferes with CFTR and AQP5 expression and localization during human airway epithelial cell differentiation. Exp Cell Res 313 (2007), 2695–2702.
30. Danahay, H., Atherton, H., Jones, G., Bridges, R.J., Poll, C.T., Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 282 (2002), L226–L236.
31. Galietta, L.J., Pagesy, P., Folli, C., Caci, E., Romio, L., Costes, B., Nicolis, E., Cabrini, G., Goossens, M., Ravazzolo, R., Zegarra-Moran, O., Il-4 is a potent modulator of ion transport in the human bronchial epithelium in vitro. J Immunol 168 (2002), 839–845.
32. Anagnostopoulou, P., Dai, L., Schatterny, J., Hirtz, S., Duerr, J., Mall, M.A., Allergic airway inflammation induces a pro-secretory epithelial ion transport phenotype in mice. Eur Respir J 36 (2010), 1436–1447.
33. Schulz, A., Tummler, B., Non-allergic asthma as a CFTR-related disorder. J Cyst Fibros 15 (2016), 641–644.
34. Hillas, G., Nikolakopoulou, S., Hussain, S., Vassilakopoulos, T., Antioxidants and mucolytics in copd management: when (if ever) and in whom?. Curr Drug Targets 14 (2013), 225–234.
35. Morrissey, B.M., Pathogenesis of bronchiectasis. Clin Chest Med 28 (2007), 289–296.
36. Russell, D.W., Gaggar, A., Solomon, G.M., Neutrophil fates in bronchiectasis and alpha-1 antitrypsin deficiency. Ann Am Thorac Soc 13:Suppl. 2 (2016), S123–S129.
37. Bergougnoux, A., Viart, V., Miro, J., Bommart, S., Molinari, N., des Georges, M., Claustres, M., Chiron, R., Taulan-Cadars, M., Should diffuse bronchiectasis still be considered a CFTR-related disorder?. J Cyst Fibros 14 (2015), 646–653.
38. Bienvenu, T., Sermet-Gaudelus, I., Burgel, P.R., Hubert, D., Crestani, B., Bassinet, L., Dusser, D., Fajac, I., Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 181 (2010), 1078–1084.
39. Rabe, K.F., Hurd, S., Anzueto, A., Barnes, P.J., Buist, S.A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., Zielinski, J., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: gold executive summary. Am J Respir Crit Care Med 176 (2007), 532–555.
40. Mannino, D.M., Copd: Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 121:Suppl. (2002), 121S–126S.
41. Drummond, M.B., Dasenbrook, E.C., Pitz, M.W., Murphy, D.J., Fan, E., Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300 (2008), 2407–2416.
42. Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Yates, J.C., Vestbo, J., Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007), 775–789.
43. Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M., A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008), 1543–1554.
44. Crim, C., Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Willits, L.R., Yates, J.C., Vestbo, J., Pneumonia risk in copd patients receiving inhaled corticosteroids alone or in combination: torch study results. Eur Respir J 34 (2009), 641–647.
45. Singh, S., Loke, Y.K., Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med, 2009.
46. Decramer, M., Rutten-van Molken, M., Dekhuijzen, P.N., Troosters, T., van Herwaarden, C., Pellegrino, R., van Schayck, C.P., Olivieri, D., Del Donno, M., De Backer, W., Lankhorst, I., et al. Effects of n-acetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on nac cost-utility study, broncus): a randomised placebo-controlled trial. Lancet 365 (2005), 1552–1560.
47. Zheng, J.P., Kang, J., Huang, S.G., Chen, P., Yao, W.Z., Yang, L., Bai, C.X., Wang, C.Z., Wang, C., Chen, B.Y., Shi, Y., et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (peace study): a randomised placebo-controlled study. Lancet 371 (2008), 2013–2018.
48. Poole, P.J., Black, P.N., Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3, 2006, CD001287.
49. Mannino, D.M., Gagnon, R.C., Petty, T.L., Lydick, E., Obstructive lung disease and low lung function in adults in the united states: data from the national health and nutrition examination survey, 1988–1994. Arch Intern Med 160 (2000), 1683–1689.
50. Dovey, M., Aitken, M.L., Emerson, J., McNamara, S., Waltz, D.A., Gibson, R.L., Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest 132 (2007), 1212–1218.
51. Chakravorty, I., Chahal, K., Austin, G., A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion. Int J Chron Obstruct Pulmon Dis 6 (2011), 693–699.
52. Saiman, L., Marshall, B.C., Mayer-Hamblett, N., Burns, J.L., Quittner, A.L., Cibene, D.A., Coquillette, S., Fieberg, A.Y., Accurso, F.J., Campbell, P.W. 3rd., Azithromycin in patients with cystic fibrosis chronically infected with pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003), 1749–1756.
53. Albert, R.K., Connett, J., Bailey, W.C., Casaburi, R., Cooper, J.A. Jr., Criner, G.J., Curtis, J.L., Dransfield, M.T., Han, M.K., Lazarus, S.C., Make, B., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365 (2011), 689–698.
54. Tummler, B., treatment of cystic fibrosis with CFTR modulators. Pneumologie 70 (2016), 301–313.
55. Solomon, G.M., Marshall, S.G., Ramsey, B.W., Rowe, S.M., Breakthrough therapies: cystic fibrosis (CF) potentiators and correctors. Pediatr Pulmonol 50:Suppl. 40 (2015), S3–S13.
56. Raju, S.V., Lin, V.Y., Liu, L., McNicholas, C.M., Karki, S., Sloane, P.A., Tang, L., Jackson, P.L., Wang, W., Wilson, L., Macon, K.J., et al. The cystic fibrosis transmembrane conductance regulator potentiator ivacaftor augments mucociliary clearance abrogating cystic fibrosis transmembrane conductance regulator inhibition by cigarette smoke. Am J Respir Cell Mol Biol 56 (2017), 99–108 In this study, the investigators show that cigarette smoke extract reduces CFTR-dependent current in human bronchial epithelial cells and human bronchi within minutes of exposure and the mechamism involved was reduction of CFTR gating. They showed that cigarette smoke extract treatment of purified CFTR resulted in acrolein modifications in amino acid residues likely to disrupt CFTR gating. Importantly, they also demonstrated that cigarette smoke extract reduced airway surface liquid depth and ciliary beat frequency and these effects could be blocked with ivacaftor coadministration in vitro.
57. Rowe, S.M., Heltshe, S.L., Gonska, T., Donaldson, S.H., Borowitz, D., Gelfond, D., Sagel, S.D., Khan, U., Mayer-Hamblett, N., Van Dalfsen, J.M., Joseloff, E., et al. Clinical mechanism of the CFTR potentiator ivacaftor in g551d-mediated cystic fibrosis. Am J Respir Crit Care Med, 2014 This clinical study evaluated invacaftor in a postapproval setting to determine mechanism of action and the response of clinically relevant markers. The results indicated that the treated patients improved in lung function, body mass index, their hospitalization rate, and in Pseudomonas aeruginasa burden, all of which illustrated the therapeutic benefit of ivacaftor.
58. Van Goor, F., Hadida, S., Grootenhuis, P.D., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., Zhou, J., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, Vx-770. Proc Natl Acad Sci U S A 106 (2009), 18825–18830 Original mauscript describing the mechanistic basis of CFTR potentiation by Vx-770 (ivacaftor).
59. Van Goor, F., Yu, H., Burton, B., Hoffman, B.J., Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibrosis 13 (2014), 29–36 In this important study, the investigators show that ivacaftor, a drug effective in patients 6 years and older who have the G551D-CFTR gating mutation, is also effective other mutant forms of CFTR. This study emphasized that this drug could provide clinical benefit for a much larger spectrum of CF patients with mild defects in either CFTR processing or in channel conductance.
60. Ren, H.Y., Grove, D.E., De La Rosa, O., Houck, S.A., Sopha, P., Van Goor, F., Hoffman, B.J., Cyr, D.M., Vx-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell 24 (2013), 3016–3024.
61. Pedemonte, N., Tomati, V., Sondo, E., Galietta, L.J., Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol, 2010.
62. Tarran, R., Loewen, M.E., Paradiso, A.M., Olsen, J.C., Gray, M.A., Argent, B.E., Boucher, R.C., Gabriel, S.E., Regulation of murine airway surface liquid volume by CFTR and Ca2+-activated Cl-conductances. J Gen Physiol 120 (2002), 407–418.
63. Tarran, R., Regulation of airway surface liquid volume and mucus transport by active ion transport. Proc Am Thorac Soc 1 (2004), 42–46.
64. Roomans, G.M., Kozlova, I., Nilsson, H., Vanthanouvong, V., Button, B., Tarran, R., Measurements of airway surface liquid height and mucus transport by fluorescence microscopy, and of ion composition by X-ray microanalysis. J Cyst Fibrosis 3:Suppl. 2 (2004), 135–139.
65. Matsui, H., Randell, S.H., Peretti, S.W., Davis, C.W., Boucher, R.C., Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Investig 102 (1998), 1125–1131.
66. Donaldson, S.H., Corcoran, T.E., Laube, B.L., Bennett, W.D., Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc Am Thorac Soc 4 (2007), 399–405.
67. Raju, S.V., Lin, V.Y., Liu, L., McNicholas, C.M., Karki, S., Sloane, P.A., Tang, L., Jackson, P.L., Wang, W., Wilson, L., Macon, K.J., et al. The CFTR potentiator ivacaftor augments mucociliary clearance abrogating CFTR inhibition by cigarette smoke. Am J Respir Cell Mol Biol, 2016.
68. Solomon, G.M., Hathorne, H., Liu, B., Raju, S.V., Reeves, G., Acosta, E.P., Dransfield, M.T., Rowe, S.M., Pilot evaluation of ivacaftor for chronic bronchitis. Lancet Respir Med 4 (2016), e32–e33 First Clinical description of Ivacaftor administration in COPD patients with the chronic bronchitis phenotype. While this study was primarily intended to demonstrate safety, early efficacy in patients with reduced CFTR function was observed in markers of CFTR function and symptoms scores.
69. Solomon, G.M., Raju, S.V., Dransfield, M.T., Rowe, S.M., Therapeutic approaches to acquired cystic fibrosis transmembrane conductance regulator dysfunction in chronic bronchitis. Ann Am Thorac Soc 13:Suppl. 2 (2016), S169–S176.
70. Rennard, S.I., Calverley, P.M., Goehring, U.M., Bredenbroker, D., Martinez, F.J., Reduction of exacerbations by the pde4 inhibitor roflumilast — the importance of defining different subsets of patients with copd. Respir Res, 12, 2011.
71. Fabbri, L.M., Calverley, P.M., Izquierdo-Alonso, J.L., Bundschuh, D.S., Brose, M., Martinez, F.J., Rabe, K.F., M. groups Ms. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374 (2009), 695–703.
72. Lambert, J.A., Raju, S.V., Tang, L.P., McNicholas, C.M., Li, Y., Courville, C.W., Faris, R.F., Coricor, G.E., Smoot, L.H., Mazur, M.M., Dransfield, M.T., et al. CFTR activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am J Respir Cell Mol Biol, 2013.
73. Tyrrell, J., Qian, X., Freire, J., Tarran, R., Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure. Am J Physiol Lung Cell Mol Physiol 308 (2015), L1068–L1077.